Anti-Amyloid-β Immunotherapy for Alzheimer’s Disease

摘要: Abstract Alzheimer’s disease (AD) currently affects 44 million people worldwide, yet there are no effective treatments to cure or prevent this devastating disease. Two major hallmarks of the AD brain extracellular plaques, containing various forms amyloid-β protein (Aβ), and intracellular neurofibrillary tangles, composed hyperphosphorylated tau protein. Active passive vaccines against Aβ have shown promise in preclinical animal models; however, translating these results safely effectively into humans has been challenging. Over past decade, some target engagement but little cognitive efficacy, possibly due late intervention patients who had symptoms for years. Many clinical trials now under way treat individuals at risk prior earliest stages decline with hope preventing delaying onset Early look promising.